ASML Holding NV
Change company Symbol lookup
Select an option...
ASML ASML Holding NV
FUN Cedar Fair LP
NWFFX American Funds New World Fund® Class F-1
CARS Cars.com Inc
AHT Ashford Hospitality Trust Inc
AHII Fyolo Technology Corp
AHH-A Armada Hoffler Properties Inc
AHH Armada Hoffler Properties Inc
AHFD Active Health Foods Inc
AGSO AgriSolar Solutions Inc
Go

Information Technology : Semiconductors & Semiconductor Equipment | Large Cap Growth
Based in Netherlands
Company profile

ASML Holding N.V. is a holding company. The Company is a manufacturer of chip-making equipment. The Company is engaged in the development, production, marketing, selling and servicing of semiconductor equipment systems, consisting of lithography systems. The Company's products include systems, and installed base products and services. The Company's principal operations are in the Netherlands, the United States and Asia. The Company offers TWINSCAN systems, equipped with lithography system with a mercury lamp as light source (i-line), Krypton Fluoride (KrF) and Argon Fluoride (ArF) light sources for 300 millimeter processing wafers for manufacturing environments for which imaging at a small resolution is required. TWINSCAN systems also include immersion lithography systems (TWINSCAN immersion systems). The Company also offers NXE systems, which are equipped with extreme ultraviolet (EUV) light source technology. The Company offers YieldStar, a wafer metrology system.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Closing Price
$366.34
Day's Change
-0.40 (-0.11%)
Bid
--
Ask
--
B/A Size
--
Day's High
370.91
Day's Low
359.93
Volume
(Average)
Volume:
912,176

10-day average volume:
933,051
912,176

UPDATE: Merck's stock rallies after profit and sales beats, raised outlook

7:04 am ET July 31, 2020 (MarketWatch)
Print

Shares of Merck & Co. Inc. (MRK) rallied 3.4% in premarket trading Friday, after the drug giant reported second-quarter profit and sales that beat expectations, while pharmaceutical sales fell from the effects of the COVID-19 pandemic, and raised its full-year outlook. Net income rose to $3.00 billion, or $1.18 a share, from $2.67 billion, or $1.03 a share, in the year-ago period. Excluding non-recurring items, adjusted earnings per share grew to $1.37 from $1.30 and beat the FactSet consensus of $1.08. Sales fell 8% to $10.87 billion, but was above the FactSet consensus of $10.44 billion, as pharmaceutical sales declined 7% to $9.68 billion. Animal health sales slipped 2% to $1.10 billion, but topped expectations of $944.6 million. The company said it estimates the negative effect of the COVID-19 pandemic on revenue to be about $1.6 billion, consisting of about $1.5 billion in pharmaceuticals and $100 million from animal health. Among Merck's biggest selling drugs, Keytruda sales rose 29% to $3.39 billion, above expectations of $3.13 billion, while Januvia/Janumet sales slipped 7% to $1.34 billion to top expectations of $1.26 billion. For 2020, the company raised its guidance ranges for adjusted EPS to $5.63 to $5.78 from $5.17 to $5.37 and for revenue to $47.2 billion to $48.7 billion from $46.1 billion to $48.1 billion. The stock has declined 13.2% year to date through Thursday, while the Dow Jones Industrial Average has lost 7.8%.

-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

July 31, 2020 07:04 ET (11:04 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.